These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 24498269)
61. Lynch syndrome in Tunisia: first description of clinical features and germline mutations. Moussa SA; Moussa A; Kourda N; Mezlini A; Abdelli N; Zerimech F; Najjar T; Jilani SB; Porchet N; Ayed FB; Manai M; Buisine MP Int J Colorectal Dis; 2011 Apr; 26(4):455-67. PubMed ID: 21311894 [TBL] [Abstract][Full Text] [Related]
62. Evolving approach and clinical significance of detecting DNA mismatch repair deficiency in colorectal carcinoma. Shia J Semin Diagn Pathol; 2015 Sep; 32(5):352-61. PubMed ID: 25716099 [TBL] [Abstract][Full Text] [Related]
63. Cancer risk and overall survival in mismatch repair proficient hereditary non-polyposis colorectal cancer, Lynch syndrome and sporadic colorectal cancer. Garre P; Martín L; Bando I; Tosar A; Llovet P; Sanz J; Romero A; de la Hoya M; Díaz-Rubio E; Caldés T Fam Cancer; 2014 Mar; 13(1):109-19. PubMed ID: 24061861 [TBL] [Abstract][Full Text] [Related]
64. Evidence for presence of mismatch repair gene expression positive Lynch syndrome cases in India. Bashyam MD; Kotapalli V; Raman R; Chaudhary AK; Yadav BK; Gowrishankar S; Uppin SG; Kongara R; Sastry RA; Vamsy M; Patnaik S; Rao S; Dsouza S; Desai D; Tester A Mol Carcinog; 2015 Dec; 54(12):1807-14. PubMed ID: 25420488 [TBL] [Abstract][Full Text] [Related]
65. Prospective immunohistochemical analysis of primary colorectal cancers for loss of mismatch repair protein expression. Lee-Kong SA; Markowitz AJ; Glogowski E; Papadopoulos C; Stadler Z; Weiser MR; Temple LK; Guillem JG Clin Colorectal Cancer; 2010 Oct; 9(4):255-9. PubMed ID: 20920999 [TBL] [Abstract][Full Text] [Related]
66. Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Geary J; Sasieni P; Houlston R; Izatt L; Eeles R; Payne SJ; Fisher S; Hodgson SV Fam Cancer; 2008; 7(2):163-72. PubMed ID: 17939062 [TBL] [Abstract][Full Text] [Related]
67. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491 [TBL] [Abstract][Full Text] [Related]
68. Are the common genetic variants associated with colorectal cancer risk for DNA mismatch repair gene mutation carriers? Win AK; Hopper JL; Buchanan DD; Young JP; Tenesa A; Dowty JG; Giles GG; Goldblatt J; Winship I; Boussioutas A; Young GP; Parry S; Baron JA; Duggan D; Gallinger S; Newcomb PA; Haile RW; Le Marchand L; Lindor NM; Jenkins MA Eur J Cancer; 2013 May; 49(7):1578-87. PubMed ID: 23434150 [TBL] [Abstract][Full Text] [Related]
69. Deficiency in DNA mismatch repair increases the rate of telomere shortening in normal human cells. Mendez-Bermudez A; Royle NJ Hum Mutat; 2011 Aug; 32(8):939-46. PubMed ID: 21538690 [TBL] [Abstract][Full Text] [Related]
70. The identification of Lynch syndrome in Congolese colorectal cancer patients. Poaty H; Aba Gandzion C; Soubeyran I; Gassaye D; Peko JF; Nkoua Bon JB; Gombé Mbalawa C Bull Cancer; 2017 Oct; 104(10):831-839. PubMed ID: 28988047 [TBL] [Abstract][Full Text] [Related]
71. [Lynch syndrome in the hands of pathologists]. Daum O; Beneš Z; Hadravský L; Stehlík J; Cerná K; Dušek M; Kokošková B; Michal M Cesk Patol; 2014 Jan; 50(1):18-24. PubMed ID: 24624982 [TBL] [Abstract][Full Text] [Related]
72. Evaluating Lynch syndrome in very early onset colorectal cancer probands without apparent polyposis. Jasperson KW; Vu TM; Schwab AL; Neklason DW; Rodriguez-Bigas MA; Burt RW; Weitzel JN Fam Cancer; 2010 Jun; 9(2):99-107. PubMed ID: 19731080 [TBL] [Abstract][Full Text] [Related]
73. Commentary on "Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome." Win AK, Lindor NM, Young JP, Macrae FA, Young GP, Williamson E, Parry S, Goldblatt J, Lipton L, Winship I, Leggett B, Tucker KM, Giles GG, Buchanan DD, Clendenning M, Rosty C, Arnold J, Levine AJ, Haile RW, Gallinger S, Le Marchand L, Newcomb PA, Hopper JL, Jenkins MA, Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, Melbourne School of Population Health, The University of Melbourne, Victoria, Australia: J Natl Cancer Inst 2012;104(18):1363-72 [Epub 2012 Aug 28]. See WA Urol Oncol; 2013 Jul; 31(5):716. PubMed ID: 23796201 [TBL] [Abstract][Full Text] [Related]
74. Low levels of microsatellite instability characterize MLH1 and MSH2 HNPCC carriers before tumor diagnosis. Alazzouzi H; Domingo E; González S; Blanco I; Armengol M; Espín E; Plaja A; Schwartz S; Capella G; Schwartz S Hum Mol Genet; 2005 Jan; 14(2):235-9. PubMed ID: 15563510 [TBL] [Abstract][Full Text] [Related]
75. Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds. Grindedal EM; Renkonen-Sinisalo L; Vasen H; Evans G; Sala P; Blanco I; Gronwald J; Apold J; Eccles DM; Sánchez AA; Sampson J; Järvinen HJ; Bertario L; Crawford GC; Stormorken AT; Maehle L; Moller P J Med Genet; 2010 Feb; 47(2):99-102. PubMed ID: 19635727 [TBL] [Abstract][Full Text] [Related]
76. Low frequency of Lynch syndrome among young patients with non-familial colorectal cancer. Goel A; Nagasaka T; Spiegel J; Meyer R; Lichliter WE; Boland CR Clin Gastroenterol Hepatol; 2010 Nov; 8(11):966-71. PubMed ID: 20655395 [TBL] [Abstract][Full Text] [Related]
77. Screening for germline mutations in mismatch repair genes in patients with Lynch syndrome by next generation sequencing. Soares BL; Brant AC; Gomes R; Pastor T; Schneider NB; Ribeiro-Dos-Santos Â; de Assumpção PP; Achatz MIW; Ashton-Prolla P; Moreira MAM Fam Cancer; 2018 Jul; 17(3):387-394. PubMed ID: 28932927 [TBL] [Abstract][Full Text] [Related]
78. Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer. Caldés T; Godino J; Sanchez A; Corbacho C; De la Hoya M; Lopez Asenjo J; Saez C; Sanz J; Benito M; Ramon Y Cajal S; Diaz-Rubio E Oncol Rep; 2004 Sep; 12(3):621-9. PubMed ID: 15289847 [TBL] [Abstract][Full Text] [Related]
79. Germline variation in the oxidative DNA repair genes NUDT1 and OGG1 is not associated with hereditary colorectal cancer or polyposis. Mur P; Jemth AS; Bevc L; Amaral N; Navarro M; Valdés-Mas R; Pons T; Aiza G; Urioste M; Valencia A; Lázaro C; Moreno V; Puente XS; Stenmark P; Warpman-Berglund U; Capellá G; Helleday T; Valle L Hum Mutat; 2018 Sep; 39(9):1214-1225. PubMed ID: 29900613 [TBL] [Abstract][Full Text] [Related]
80. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Loughrey MB; Waring PM; Tan A; Trivett M; Kovalenko S; Beshay V; Young MA; McArthur G; Boussioutas A; Dobrovic A Fam Cancer; 2007; 6(3):301-10. PubMed ID: 17453358 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]